Eli Lilly and Company (NYSE:LLY) is one of the 13 Best Low Risk High Growth Stocks to Buy. Amid carrying on new studies, the ...

Eli Lilly (LLY) recently entered a collaboration with Gate Bioscience to develop molecular gate therapeutics, a move that ...

Eli Lilly outpaces Novo in the GLP-1 market with Tirzepatide and emerging blockbusters, signaling future growth. Read more on ...

DelveInsight’s, “Diabetes Pipeline Insight 2025” report provides comprehensive insights about 200+ companies and 200+ ...

The rising occurrence of dysmenorrhea, along with greater awareness and advancements in diagnosis, is driving substantial growth in the dysmenorrhea ...

The drugmaker has invested $10 billion in Wake and Durham counties over the past 30 years. Biogen says that figure will ...

Biogen will invest an extra $2 billion to expand its RTP facilities, focusing on AI-driven manufacturing and late-stage ...

Therapeutics Market, valued at approximately USD 143.95 billion in 2023, is projected to witness strong expansion over the forecast period, reaching an estimated valuation exceeding USD 270 billion by ...

In July 2025, Inovio Pharmaceuticals conducted a Phase 1/2 trial to evaluate safety, immunogenicity and preliminary efficacy of INO-5401 and INO-9012 in combination with cemiplimab (REGN2810), with ...

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same ...